Expert Insights on Novel NMOSD Treatments : Episode 9
Opinion
Video
Long-term NMOSD Data
Author(s):
Key Takeaways
- Satralizumab and inebilizumab demonstrate sustained efficacy and favorable safety profiles in NMOSD management, reducing relapse rates significantly.
- Satralizumab targets interleukin-6 receptors, while inebilizumab targets CD19, both contributing to reduced relapse rates in NMOSD patients.
Sean Pittock, MD, discusses the long-term efficacy and safety results of other FDA-approved treatments for neuromyelitis optica spectrum disorder, including satralizumab, inebilizumab, and the off-label use of rituximab.
EP: 1.Relapses and Disability Accumulation in NMOSD
EP: 2.Treatments With Higher Efficacy and Relapses in NMOSD
EP: 3.Ravulizumab Long-Term Data and Management of NMOSD
EP: 4.The Evolving Understanding of NMOSD Pathophysiology and the Role of Complement System
EP: 5.Treatment Options to Manage and Prevent Relapses in NMOSD
EP: 6.Importance of Diverse Mechanisms of Action to Effectively Treat NMOSD
EP: 7.Complement Inhibitors in NMOSD
EP: 8.Meningococcal Infection and NMOSD
Now Viewing
EP: 9.Long-term NMOSD Data
EP: 10.Use of Long-term NMOSD Data in Clinical Practice
Video content above is prompted by the following:
Can you also comment on long-term efficacy and safety results with other FDA-approved treatments, including satralizumab, inebilizumab, and off-label use of rituximab?
Related Videos
Related Content
